PET in Guiding Cervical Lymphadenectomy (ECTOP-2003) (PETCLMESCC)
The Utility of Positron Emission Tomography (PET) in Predicting Cervical Lymphatic Metastasis for Mid-lower Thoracic Esophageal Squamous Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Beijing
-
Beijing, Beijing, China, 100021
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Medical University Cancer Hospital
-
-
Jiangsu
-
Yangzhou, Jiangsu, China
- Jiangdu people's hospital of Yangzhou
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically proven esophageal cancer
- Resectable cT1-T3/N0-N1 thoracic,operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, and barium swallow
- Karnofsky performance status greater than or equal to 80%
- Acceptable pulmonary and cardiac function.
- Acceptable hepatic, renal and bone marrow function
Exclusion Criteria:
- Low performance status(Karnofsky score <80%)
- Past history of malignancy
- Unresectable advanced disease(T4 or M1a,M1b)
- Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment
- Medically unfit for surgical resection
- Pulmonary reserve inadequate to undergo thoracotomy and extensive mediastinal lymphadenectomy.
- A significant history of unstable cardiovascular disease that in the opinion of the treating physician should preclude the patient from protocol treatment.
- Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.
- Significant psychiatric illness that would interfere with patient compliance
- Severe hepatic cirrhosis or with serious renal disease unacceptable for surgery
- Salvage surgery after definitive chemoradiotherapy
- Patients have neoadjuvant chemoradiotherapy
- Above the age of 80 years
- Unreliable for follow up
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cervical lymph node metastasis
Time Frame: Decembear 2018
|
postoperative pathological examination
|
Decembear 2018
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mediastinal and abdonimal lymph nodes metastasis
Time Frame: Novermber 2018
|
postoperative pathological examination
|
Novermber 2018
|
|
postoperative complications
Time Frame: March 2019
|
surgical morbidity and mortality
|
March 2019
|
|
diseases-free survival
Time Frame: November 2021
|
from the time of surgery to the time of first recurrence or death
|
November 2021
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Haiquan Chen, MD, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PETCLM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.